Effects of Intravitreal Aflibercept on Galectin-1 and Vascular Endothelial Growth Factor-A Plasma Levels in Patients with Diabetic Retinopathy

References

• Cheung N, Mitchell P, Wong TY. Diabetic retinopathy. Lancet. 2010;376(9735):124–36. doi:10.1016/S0140-6736(09)62124-3.
   PubMed Web of Science ®Google Scholar
• Moss SE, Klein R, Klein BE. The 14-year incidence of visual loss in a diabetic population. Ophthalmology. 1998;105(6):998–1003. doi:10.1016/S0161-6420(98)96025-0.
   PubMed Web of Science ®Google Scholar
• Ding J, Wong TY. Current epidemiology of diabetic retinopathy and diabetic macular edema. Curr Diab Rep. 2012;12(4):346–54. doi:10.1007/s11892-012-0283-6.
   PubMed Web of Science ®Google Scholar
• Das A, McGuire PG, Monickaraj F. Novel pharmacotherapies in diabetic retinopathy: current status and what’s in the horizon? Indian J Ophthalmol. 2016;64(1):4–13. doi:10.4103/0301-4738.178154.
   PubMed Web of Science ®Google Scholar
• Cohen SR, Gardner TW. Diabetic retinopathy and diabetic macular edema. Dev Ophthalmol. 2016;55:137–46.
   PubMedGoogle Scholar
• Roy S, Kern TS, Song B, Stuebe C. Mechanistic insights into pathological changes in the diabetic retina: implications for targeting diabetic retinopathy. Am J Pathol. 2017;187(1):9–19. doi:10.1016/j.ajpath.2016.08.022.
   PubMed Web of Science ®Google Scholar
• Das A, McGuire PG. Retinal and choroidal angiogenesis: pathophysiology and strategies for inhibition. Prog Retin Eye Res. 2003;22(6):721–48. doi:10.1016/j.preteyeres.2003.08.001.
   PubMed Web of Science ®Google Scholar
• Aiello LP, Avery RL, Arrigg PG, Keyt BA, Jampel HD, Shah ST, Pasquale LR, Thieme H, Iwamoto MA, Park JE, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med. 1994;331(22):1480–87. doi:10.1056/NEJM199412013312203.
   PubMed Web of Science ®Google Scholar
• Funatsu H, Noma H, Mimura T, Eguchi S, Hori S. Association of vitreous inflammatory factors with diabetic macular edema. Ophthalmology. 2009;116(1):73–79. doi:10.1016/j.ophtha.2008.09.037.
   PubMed Web of Science ®Google Scholar
• Funk M, Schmidinger G, Maar N, Bolz M, Benesch T, Zlabinger GJ, Schmidt-Erfurth UM. Angiogenic and inflammatory markers in the intraocular fluid of eyes with diabetic macular edema and influence of therapy with bevacizumab. Retina. 2010;30(9):1412–19. doi:10.1097/IAE.0b013e3181e095c0.
   PubMed Web of Science ®Google Scholar
• Holash J, Davis S, Papadopoulos N, Croll SD, Ho L, Russell M, Boland P, Leidich R, Hylton D, Burova E, et al. VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci U S A. 2002;99(17):11393–98. doi:10.1073/pnas.172398299.
   PubMed Web of Science ®Google Scholar
• Kanda A, Noda K, Saito W, Ishida S. Aflibercept Traps Galectin-1, an Angiogenic Factor Associated with Diabetic Retinopathy. Sci Rep. 2015;5:17946. doi:10.1038/srep17946.
   PubMed Web of Science ®Google Scholar
• Thijssen VL, Heusschen R, Caers J, Griffioen AW. Galectin expression in cancer diagnosis and prognosis: A systematic review. Biochim Biophys Acta. 2015;1855(2):235–47.
   PubMed Web of Science ®Google Scholar
• Chong Y, Tang D, Gao J, Jiang X, Xu C, Xiong Q, et al. Galectin-1 induces invasion and the epithelial-mesenchymal transition in human gastric cancer cells via non-canonical activation of the hedgehog signaling pathway. Oncotarget. 2016;7(50):83611–26.
   PubMed Web of Science ®Google Scholar
• Croci DO, Cerliani JP, Dalotto-Moreno T, Méndez-Huergo SP, Mascanfroni ID, Dergan-Dylon S, Toscano M, Caramelo J, García-Vallejo J, Ouyang J, et al. Glycosylation-dependent lectin-receptor interactions preserve angiogenesis in anti-VEGF refractory tumors. Cell. 2014;156(4):744–58. doi:10.1016/j.cell.2014.01.043.
   PubMed Web of Science ®Google Scholar
• Wang X, Sawada T, Sawada O, Saishin Y, Liu P, Ohji M. Serum and plasma vascular endothelial growth factor concentrations before and after intravitreal injection of aflibercept or ranibizumab for age-related macular degeneration. Am J Ophthalmol. 2014;158(4):738–44e1. doi:10.1016/j.ajo.2014.06.009.
   PubMed Web of Science ®Google Scholar
• Yoshida I, Shiba T, Taniguchi H, Takahashi M, Murano T, Hiruta N, Hori Y, Bujo H, Maeno T. Evaluation of plasma vascular endothelial growth factor levels after intravitreal injection of ranibizumab and aflibercept for exudative age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 2014;252(9):1483–89. doi:10.1007/s00417-014-2717-0.
   PubMed Web of Science ®Google Scholar
• Zehetner C, Kralinger MT, Modi YS, Waltl I, Ulmer H, Kirchmair R, Bechrakis NE, Kieselbach GF. Systemic levels of vascular endothelial growth factor before and after intravitreal injection of aflibercept or ranibizumab in patients with age-related macular degeneration: a randomised, prospective trial. Acta Ophthalmol. 2015;93(2):e154–9. doi:10.1111/aos.2015.93.issue-2.
   PubMed Web of Science ®Google Scholar
• Avery RL, Castellarin AA, Steinle NC, Dhoot DS, Pieramici DJ, See R, Couvillion S, Nasir MA, Rabena MD, Maia M, et al. Systemic pharmacokinetics and pharmacodynamics of intravitreal aflibercept, bevacizumab, and ranibizumab. Retina. 2017;37:1847–58. doi:10.1097/IAE.0000000000001493.
   PubMed Web of Science ®Google Scholar
• Diabetic Retinopathy Clinical Research N, Wells JA, Glassman AR, Ayala AR, Jampol LM, Aiello LP, et al. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. N Engl J Med. 2015;372(13):1193–203. doi:10.1056/NEJMoa1414264.
   PubMed Web of Science ®Google Scholar
• Heier JS, Bressler NM, Avery RL, Bakri SJ, Boyer DS, Brown DM, Dugel PU, Freund KB, Glassman AR, Kim JE, et al. Comparison of aflibercept, bevacizumab, and ranibizumab for treatment of diabetic macular edema: extrapolation of data to clinical practice. JAMA Ophthalmol. 2016;134(1):95–99. doi:10.1001/jamaophthalmol.2015.4110.
   PubMed Web of Science ®Google Scholar
• Wilkinson CP, Ferris FL 3rd, Klein RE, Lee PP, Agardh CD, Davis M, Dills D, Kampik A, Pararajasegaram R, Verdaguer JT. Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales. Ophthalmology. 2003;110(9):1677–82. doi:10.1016/S0161-6420(03)00475-5.
   PubMed Web of Science ®Google Scholar
• Ferrara N, Gerber H-P, LeCouter J. The biology of VEGF and its receptors. Nat Med. 2003;9(6):669–76. doi:10.1038/nm0603-669.
   PubMed Web of Science ®Google Scholar
• Takahashi H, Shibuya M. The vascular endothelial growth factor (VEGF)/VEGF receptor system and its role under physiological and pathological conditions. Clin Sci (Lond). 2005;109(3):227–41. doi:10.1042/CS20040370.
   PubMed Web of Science ®Google Scholar
• Uehara F, Ohba N, Ozawa M. Isolation and characterization of galectins in the mammalian retina. Invest Ophthalmol Vis Sci. 2001;42(10):2164–72.
   PubMed Web of Science ®Google Scholar
• Ridano ME, Subirada PV, Paz MC, Lorenc VE, Stupirski JC, Gramajo AL, Luna JD, Croci DO, Rabinovich GA, Sánchez MC. Galectin-1 expression imprints a neurovascular phenotype in proliferative retinopathies and delineates responses to anti-VEGF. Oncotarget. 2017. doi:10.18632/oncotarget.17129.
   PubMedGoogle Scholar
• Papadopoulos N, Martin J, Ruan Q, Rafique A, Rosconi MP, Shi E, Pyles EA, Yancopoulos GD, Stahl N, Wiegand SJ. Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab. Angiogenesis. 2012;15(2):171–85. doi:10.1007/s10456-011-9249-6.
   PubMed Web of Science ®Google Scholar
• Powner MB, McKenzie JA, Christianson GJ, Roopenian DC, Fruttiger M. Expression of neonatal Fc receptor in the eye. Invest Ophthalmol Vis Sci. 2014;55(3):1607–15. doi:10.1167/iovs.13-12574.
   PubMed Web of Science ®Google Scholar
• Zehetner C, Bechrakis NE, Stattin M, Kirchmair R, Ulmer H, Kralinger MT, Kieselbach GF. Systemic counterregulatory response of placental growth factor levels to intravitreal aflibercept therapy. Invest Ophthalmol Vis Sci. 2015;56(5):3279–86. doi:10.1167/iovs.15-16686.
   PubMed Web of Science ®Google Scholar
• Bolinger MT, Antonetti DA. Moving Past Anti-VEGF: novel therapies for treating diabetic retinopathy. Int J Mol Sci. 2016;17(9). doi:10.3390/ijms17091498.
   PubMed Web of Science ®Google Scholar
• Montassar F, Darche M, Blaizot A, Augustin S, Conart J-B, Millet A, Elayeb M, Sahel J-A, Réaux-Le Goazigo A, Sennlaub F, et al. Lebecetin, a C-type lectin, inhibits choroidal and retinal neovascularization. Faseb J. 2017;31(3):1107–19. doi:10.1096/fj.201600351R.
   PubMed Web of Science ®Google Scholar
• Croci DO, Mendez-Huergo SP, Cerliani JP, Rabinovich GA. Immune-mediated and hypoxia-regulated programs: accomplices in resistance to anti-angiogenic therapies. In Handbook of experimental pharmacology. Berlin, Heidelberg: Springer; 2017.
   Google Scholar
• Gunsilius E, Petzer A, Stockhammer G, Nussbaumer W, Schumacher P, Clausen J, Gastl G. Thrombocytes are the major source for soluble vascular endothelial growth factor in peripheral blood. Oncology. 2000;58(2):169–74. doi:10.1159/000012095.
   PubMed Web of Science ®Google Scholar
• Walz JM, Boehringer D, Deissler HL, Faerber L, Goepfert JC, Heiduschka P, Kleeberger SM, Klettner A, Krohne TU, Schneiderhan-Marra N, et al. Pre-analytical parameters affecting vascular endothelial growth factor measurement in plasma: identifying confounders. PLoS One. 2016;11(1):e0145375. doi:10.1371/journal.pone.0145375.
   PubMed Web of Science ®Google Scholar
• Aguilar-Mahecha A, Kuzyk MA, Domanski D, Borchers CH, Basik M, Krauss-Etschmann S. The effect of pre-analytical variability on the measurement of MRM-MS-based mid- to high-abundance plasma protein biomarkers and a panel of cytokines. PLoS One. 2012;7(6):e38290. doi:10.1371/journal.pone.0038290.
   PubMed Web of Science ®Google Scholar
• Schlingemann RO, Van Noorden CJ, Diekman MJ, Tiller A, Meijers JC, Koolwijk P, Wiersinga WM. VEGF levels in plasma in relation to platelet activation, glycemic control, and microvascular complications in type 1 diabetes. Diabetes Care. 2013;36(6):1629–34. doi:10.2337/dc12-1951.
   PubMed Web of Science ®Google Scholar
• Niers TMH, Richel DJ, Meijers JCM, Schlingemann RO, Lee T. Vascular endothelial growth factor in the circulation in cancer patients may not be a relevant biomarker. PLoS One. 2011;6(5):e19873. doi:10.1371/journal.pone.0019873.
   PubMed Web of Science ®Google Scholar